NCT03512405
Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia
At risk: Primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 18 versions: 15 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Results posted: Nov 17, 2026 Show 8 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria shortened, about 6 words
- Final enrollment: 26 participants (planned 36)
- Primary completion date changed from estimate of Nov 11, 2025 to Jan 31, 2025
- Study completion pushed from Nov 11, 2025 to Sep 29, 2027
- Secondary endpoints revised (9)
- Study description revised
- Publications: details revised at 1 of 1 entry
- Minor Trial status: Recruiting to Active, Not Recruiting
- Primary and study completion dates: Oct 30, 2025 to Nov 11, 2025
- Site details revised
- Notable Primary and study completion dates: Oct 30, 2024 to Oct 30, 2025v16
- Notable Primary and study completion dates: Apr 15, 2024 to Oct 30, 2024v15
- Notable Primary and study completion dates: Apr 2022 to Apr 15, 2024v12
Show 9 earlier versionsHide 9 earlier versions
- Notable Trial status: Suspended to Recruiting
- Site details revised
- Stopped Trial status: Recruiting to Suspended Sponsor's reason: pending intrim analysis
- Site details revised
- Minor Start date changed from estimate of Sep 2019 to Aug 2, 2019v8
- Notable Primary and study completion dates: Mar 21, 2021 to Apr 2022
- Start date: Jun 1, 2019 to Sep 2019
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised
- Notable Start date: Apr 1, 2019 to Jun 1, 2019v5
Notable Trial status: Withdrawn to Not Yet Recruitingv4 Show 6 more changesShow less
- Start date: Dec 21, 2018 to Apr 1, 2019
- Primary endpoints revised (2)
- Enrollment target: 0 to 36
- Secondary endpoints: 13 to 9
- Study description expanded, about 18 words
- Site contact updated
- Stopped Trial status: Not Yet Recruiting to Withdrawn Sponsor's reason: Contract not executed
- Enrollment target: estimated 35 to confirmed 0
- Site contact updated
- Notable Start date: Sep 21, 2018 to Dec 21, 2018v2
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of Dose-Limiting Toxicity (Phase 1)
Timeframe: From the start of initial treatment up to 35 days
Response Rate (Phase 2)
Timeframe: From the start of initial treatment till the end of protocol treatment, up to 5 cycles
Secondary (9)
Incidence of Grade 3-5 Adverse Events
Duration of Remission
Time to Response
Median Overall Survival
Incidence of Relapse
Show 4 moreShow less
Allogeneic Stem Cell Transplantation (SCT) Realization Rate
Number and Proportion of Patients Who Start Pembrolizumab Maintenance
Number and Proportion of Patients Who Complete Pembrolizumab Maintenance
Minimal Residual Disease Rate
Arms and interventions
Treatment (pembrolizumab, blinatumomab)Experimental
Participants receive pembrolizumab intravenously (IV) over 30 minutes on day 15 of cycle 1 and days 1 and 22 of cycles 2 -5, and blinatumomab IV on days 1-28. Treatment repeats every 35-42 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response have the option to receive blinatumomab IV for up to 4 additional cycles.
Biologicals: Blinatumomab, Pembrolizumab
Other: Laboratory Biomarker Analysis
Sites
1 site in 1 country
- City of Hope Medical CenterDuarte, California, United States